Ацетилсалициловая кислота

1. Ruggeri ZM. Plateletsinatherothrombosis. Nature Med 2002; 8: 1227–34.
2. Montalescot G, Sechtem U, Achenbach S et al. 2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J 2013; 34 (38): 2949–3003.
3. Steg PG, James SK, Atar D, Badano LP et al. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J 2012; 33 (20): 2569–619.
4. Hamm CW, Bassand JP, Agewall S et al. European Society of Cardiology. ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. G Ital Cardiol 2012; 13 (3): 171–228.
5. Mancia G, Fagard R, Narkiewicz K et al. Task Force Members. 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2013; 31 (7): 1281–357.
6. Fuster V, Sweeny J. Aspirin: A Historical and Contemporary Therapeutic Overview. Circulation 2011; 123: 768–78.
7. Patrono C, Baigent C, Hirsh J, Roth G. Antiplatelet Drugs. Chest 2008; 133 (Suppl. 6): 199S–233S.
8. Elwood P, Cochrane A, Burr M et al. A Randomized Controlled Trial of Acetyl Salicyclic Acid in the Secondary Prevention of Mortality from Myocardial Infarction. BMJ 1974; 1 (5905): 436–40.
9. Antiplatelet Trialists’ Collaboration. Collaborative overview of randomized trials of antiplatelet therapy: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994; 308: 81–106.
10. The SALT Collaborative Group. Swedish Aspirin Low dose Trial (Salt) of 75 mg aspirin as secondary prophylaxis after cerebrovascular ischemic events. BMJ 1991; 338: 1345–9.
11. UK-TIA Study Group. United Kingdom transient ischemic attack (UK-TIA) aspirin trial: final results. J Neurol Neurosurg Psychiatr 1991; 54: 1044–54.
12. Antithrombotic Trials~Collaboration. Prevantion of death, myocardial infarction and stroke by antiplatelet therapy in high-risk patients. BMJ 2002; 324: 71–86.
13. Savage MP, Goldberg S, Bove AA et al. Effect of thromboxane A2 blokade on clinical outcome and restenosis after successful coronary angioplasty. Multi-Hospital Eastern Atlantic Restenosis Trial (M-HEART II). Circulation 1995; 92: 3194–200.
14. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation The Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC). Eur Heart J 2012; 33: 2569–619.
15. 2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction: Executive Summary: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. Published online: December 17, 2012.
16. Ridker P, Manson J, Gaziano J et al. Low-dose aspirin therapy for chronic stable angina. A randomized, placebo-controlled clinical trial. Ann Intern Med 1991; 114 (10): 835–9.
17. Juul-Möller S, Edvardsson N, Jahnmatz B et al. Double-blind trial of aspirin in primary prevention of myocardial infarction in patients with stable chronic angina pectoris. The Swedish Angina Pectoris Aspirin Trial (SAPAT) Group. Lancet 1992; 340 (8833): 1421–5.
18. Tendera M, Aboyans V, Bartelink ML et al. ESC Guidelines on the diagnosis and treatment of peripheral artery diseases: Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries: the Task Force on the Diagnosis and Treatment of Peripheral Artery Diseases of the European Society of Cardiology (ESC). Eur Heart J 2011; 32 (22): 2851–906.
19. Hansson L, Zanchetti A, Carruthers SG et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998; 351: 1755–62.
20. Ridker PM, Cook NR, Lee IM et al. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med 2005; 352: 1293–304.
21. Baigent C, Blackwell L, Collins R et al. Antithrombotic Trialists’ (ATT) Collaboration. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 2009; 373: 1849–60.
22. Seshasai S, Wijesuriya S, Sivakumaran R et al. Effect of aspirin on vascular and nonvascular outcomes: meta-analysis of randomized controlled trials. Arch Intern Med 2012; 172 (3): 209–16.
23. Weil J, Colin-Jones D, Langman M et al. Prophylactic aspirin and risk of peptic ulcer bleeding. BMJ 1995; 310 (6983): 827–30.
24. Serebruany VL, Steinhubl SR, Berger PV et al. Analysis of risk of bleeding complications after different doses of aspirin in 192,036 patients enrolled in 31 randomized controlled trials. Am J Cardiology 2005; 95 (10): 1218–22.
25. Cryer B. Gastrointestinal Safety of Low-Dose Aspirin. Am J Manag Care 2002; 8: S701–S708.
26. Ng W, Wong WM, Chen WH et al. Incidence and predictors of upper gastrointestinal bleeding in patients receiving low-dose aspirin for secondary prevention of cardiovascular events in patients with coronary artery disease. World J Gastroenterol 2006; 12 (18): 2923–37.
27. Sakamoto C, Sugano K, Ota S. Case-control study on the association of upper gastrointestinal bleeding and nonsteroidal anti-inflammatory drugs in Japan. Eur J Clin Pharmacol 2006; 62 (9): 765–72.
28. Henry D, Dobson A, Truner C. Variability in the risk of major gastrointestinal complications from nonaspirin nonsteroidal anti-inflammatory drugs. Gastroenterology 1993; 105: 1078–88.
29. Pedersen A., FitzGerald G. Dose-related kinetics of aspirin. Presystemic acetylation of platelet cyclooxygenase. N Engl J Med 1984; 311: 1206–11.
30. Saini SD, Fendrick AM, Scheiman JM. Cost-effectiveness analysis: cardiovascular benefits of proton pump inhibitor co-therapy in patients using aspirin for secondary prevention. Aliment Pharmacol Ther 2011; 34 (2): 243–51.

Д.А.Сычев

ГБОУ ДПО РМАПО Минздрава России, Москва